Key Highlights

  • Proteomics launched controlled releases of PromarkerD and PromarkerEso across WA and the NT.
  • Healius offers access to about 1,900 collection centres under the distribution agreement.
  • Private-pay prices begin at AUD 495 for PromarkerD and AUD 997 for PromarkerEso.
  • The companies expect broader commercial sales during the second quarter of FY27.

Proteomics International Laboratories Limited (ASX:PIQ) has moved two Promarker blood tests from distribution planning into controlled market use. PromarkerD and PromarkerEso are initially available in Western Australia and the Northern Territory through the company’s exclusive Australian pathology distribution agreement with Healius Limited (ASX:HLS), ahead of a proposed wider rollout.

Healius Provides the Collection Network

Healius became the exclusive Australian pathology distributor for the Promarker portfolio in July 2026. Its network covers approximately 1,900 collection centres and existing referral channels. Healius will manage specimen collection, pathology distribution and commercial delivery to primary-care and specialist referrers. Proteomics International retains responsibility for laboratory analysis, clinical reporting, scientific support, quality systems and regulatory compliance.

Two Tests Lead the Commercial Introduction

PromarkerD assesses the risk of diabetic kidney disease as much as four years before clinical symptoms emerge. PromarkerEso is designed to help rule out oesophageal cancer in people with chronic reflux. During the controlled phase, the tests carry private-pay prices of AUD 495 and AUD 997 respectively. Wider commercial sales are expected in the second quarter of FY27, subject to successful implementation.

A Third Test Remains in Development

PromarkerEndo, intended to assist diagnosis of endometriosis, is progressing through assay refinement and validation. Its next clinical milestone depends on the outcome of that work and follows a separate development timetable from the two tests already entering the market. The staged approach allows operational systems for PromarkerD and PromarkerEso to be assessed before broader availability.

Adoption Will Determine the Commercial Result

The company cannot yet estimate Revenue from the distribution agreement reliably. Ordering volumes may depend on clinician awareness, demonstrated clinical utility, referral behaviour, price and reimbursement. A private-pay model may also affect accessibility. Specimen transfer, reporting and information flows must operate consistently between the organisations as the release expands.

Metrics Move beyond Network Size

Completion of implementation work and the start of broader sales are the next formal steps. Test volumes, repeat referrals, commercial receipts and reimbursement progress would show whether availability is translating into use. Proteomics International may also report how laboratory capacity and clinical-reporting processes scale as access moves beyond the initial regions.